Vaccination with BLP25 liposome vaccine to treat non-small cell lung and prostate cancers

Expert Rev Vaccines. 2005 Jun;4(3):249-57. doi: 10.1586/14760584.4.3.249.

Abstract

The identification of tumor-associated/-specific antigens and an increased understanding of the ways in which antigens are processed and presented has led to a revived interest in cancer vaccines as a therapeutic strategy. BLP25 liposome (L-BLP25) vaccine is a cancer vaccine that targets the exposed core peptide of the MUC1 tumor-associated antigen. Studies in advanced-stage non-small cell lung cancer demonstrate that L-BLP25 vaccine has the potential to extend the survival of patients with Stage IIIB locoregional non-small cell lung cancer and maintain quality of life for longer. L-BLP25 vaccine also shows promise for prostate cancer patients, having the potential to prolong prostate-specific antigen doubling time in men with biochemical failure post prostatectomy. These clinically meaningful results with a relatively nontoxic therapeutic vaccine are very encouraging and suggest potential for L-BLP25 to fulfill an unmet medical need.

Publication types

  • Review

MeSH terms

  • Animals
  • Cancer Vaccines / therapeutic use*
  • Carcinoma, Non-Small-Cell Lung / immunology
  • Carcinoma, Non-Small-Cell Lung / prevention & control*
  • Humans
  • Liposomes
  • Lung Neoplasms / immunology
  • Lung Neoplasms / prevention & control*
  • Male
  • Prostatic Neoplasms / immunology
  • Prostatic Neoplasms / prevention & control*

Substances

  • Cancer Vaccines
  • Liposomes